/* HOTJAR */
Free worldwide shipping

Can Rapamycin Slow Aging in Dogs? New Research Shows Promise Dog Aging Project Marks Milestone in Landmark TRIAD Study

The Dog Aging Project has reached an exciting milestone in its landmark study on healthy aging in dogs. The project recently announced that the first participants—Zoe and Jack—have completed their full three-year involvement in the Test of Rapamycin in Aging Dogs (TRIAD), a groundbreaking clinical trial exploring whether the drug rapamycin can slow or mitigate the effects of aging in dogs.

This is the third and largest clinical trial of its kind, with the goal of enrolling 580 dogs across the United States. TRIAD builds on earlier research suggesting that small, carefully administered doses of rapamycin may help delay age-related diseases and improve overall healthspan in older dogs.

A New Frontier in Canine (and Human) Aging

Rapamycin, an immunosuppressive drug originally developed for organ transplant recipients, has emerged in recent years as a leading candidate in anti-aging research. In laboratory animals, rapamycin has shown potential to extend lifespan and delay the onset of age-associated diseases such as cancer, cognitive decline, and heart disease. Now, researchers hope those benefits may translate to companion dogs—and possibly, eventually, humans.

“Zoe and Jack’s completion of the trial marks a major step forward,” said researchers with the Dog Aging Project. “We are learning more every day about how we might improve the quality and length of life not just for dogs, but potentially for people as well.”

How TRIAD Works

To be eligible for TRIAD, dogs must meet several criteria:

  • Age 7 years or older
  • Weight between 44 and 120 pounds
  • Spayed or neutered
  • In overall good health

Owners must commit to bringing their dogs to a clinical trial site every six months over the course of three years. Trial locations are spread across the U.S., including in Wheat Ridge and Fort Collins, Colorado.

Veterinarians are encouraged to inform clients about the study. Educational materials and enrollment details are available on the Dog Aging Project website.

A Collaborative Scientific Effort

The Dog Aging Project is a large-scale, community science initiative led by Texas A&M University, the University of Washington, and Tufts University, in collaboration with numerous research institutions. The project received a significant funding boost in 2024 with a $7 million grant from the National Institutes of Health (NIH), in addition to ongoing philanthropic support and backing from the Dog Aging Institute.

The TRIAD study is just one piece of the larger Dog Aging Project, which aims to understand the biological, genetic, and environmental factors that influence canine aging.

Latest news

Drug combination found to extend lifespan by 30 per cent “INDEPENDENT”

Rapamycin Shows Promise in Preventing Feline Heart Disease FDA Approves New Drug for Early-Stage HCM; New Study Seeks to Confirm Long-Term Benefits

Weekly Rapamycin Shows Promise in Improving Symptoms of ME/CFS in Early Clinical Trial

The Revolution that Extend Lifes

Muscle Strength and Endurance in Older Adults with Rapamycin